Genetic engineering of dendritic cells to express immunosuppressive molecules (viral IL-10, TGF-β, and CTLA4Ig)
L Lu, WC Lee, T Takayama, S Qian… - Journal of leukocyte …, 1999 - academic.oup.com
L Lu, WC Lee, T Takayama, S Qian, A Gambotto, PD Robbins, AW Thomson
Journal of leukocyte biology, 1999•academic.oup.comThere is growing evidence that, in addition to their role as initiators of immune responses,
dendritic cells (DC) can exhibit tolerogenic properties. Immature DC deficient in cell surface
costimulatory/accessory molecules can prolong organ and pancreatic islet allograft survival,
whereas in vitro manipulation of DC by exposure to a variety of factors (eg, viral interleukin-
10; CTLA4Ig) can confer tolerogenic properties on these cells. Genetic engineering of DC to
express immunosuppressive molecules is, in theory, an attractive approach to the therapy of …
dendritic cells (DC) can exhibit tolerogenic properties. Immature DC deficient in cell surface
costimulatory/accessory molecules can prolong organ and pancreatic islet allograft survival,
whereas in vitro manipulation of DC by exposure to a variety of factors (eg, viral interleukin-
10; CTLA4Ig) can confer tolerogenic properties on these cells. Genetic engineering of DC to
express immunosuppressive molecules is, in theory, an attractive approach to the therapy of …
Abstract
There is growing evidence that, in addition to their role as initiators of immune responses, dendritic cells (DC) can exhibit tolerogenic properties. Immature DC deficient in cell surface costimulatory/accessory molecules can prolong organ and pancreatic islet allograft survival, whereas in vitro manipulation of DC by exposure to a variety of factors (e.g., viral interleukin-10; CTLA4Ig) can confer tolerogenic properties on these cells. Genetic engineering of DC to express immunosuppressive molecules is, in theory, an attractive approach to the therapy of allograft rejection and possibly, autoimmune disorders. J. Leukoc. Biol. 66: 293–296; 1999.
Oxford University Press